TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00208975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF
Description: Initial patients (n=9) received fludarabine (25 mg/m\^2 intravenously) and mitoxantrone (10 mg/m\^2 intravenously)with sequential administration of GM-CSF(Granulocyte-macrophage colony stimulating factor) (500 µcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m\^2) on day 8.~After a change in the protocol, all additional patients (n=6) received fludarabine (25 mg/m\^2 intravenously) and cyclophosphamide (250 mg/m\^2 intravenously)with sequential administration of GM-CSF (500 µcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m\^2) on day 8. All patients received additional doses of GM-CSF (days +8 through +14) were given for patients to reduce variability in neutropenic management.
Study: NCT01777724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination of Triple P Discussion Groups and Stress Control
Description: The intervention consists of eight group sessions: two 120 minute Triple P Discussion Group sessions (http://www.triplep.net/), and six 90 minute Stress Control sessions (http://glasgowsteps.com/home.php).
Study: NCT04244539

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-intensity laser Device.
Description: Twenty four treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 8 weeks in succession via HIRO® 3.0 device (ASAlaser, Arcugnano, Vicenza, Italy). The device gives pulsed emission (λ = 1064 nm), maximum power (3000 W), fluency range (360-1780 mJ/cm2), pulse duration (≤ 100 μs), frequency range (10-40 Hz), maximum energy per pulse (350 mJ), mean power (10.5 W), and power cycle of \~0.1%.
Study: NCT01008345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: Patients will receive 10 mg/day of ezetimibe for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ezetimibe
Description: Patients will receive 10 mg/day of ezetimibe for 8 weeks
Study: NCT03691415

Intervention type: DRUG
Intervention: BELKYRA Inj.
Description: Patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart.
Study: NCT01824979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP mask ( Pilairo)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Other CPAP mask
Study: NCT03720457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human CD19 targeted T Cells Injection
Description: Autologous genetically modified anti-CD19 CAR transduced T cells
Study: NCT04336163

Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Coherence Tomography
Description: Skin imaging to determine vascular characteristics such as plexus depth, vessel diameter, and vessel density.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Skin imaging to determine vascular characteristics such as plexus depth, vessel diameter, and vessel density.
Study: NCT03573167

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Motivational Interviewing (MI)
Description: This is a counseling intervention to support behavior change conducted in-person (face-to-face) between the investigator and the participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Motivational Interviewing (MI)
Description: This is a counseling intervention to support behavior change conducted entirely over the mobile phone between the investigator and the participant
Study: NCT03728881

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Bivalent Vaccine
Description: Given IM
Study: NCT03089307

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dornier Aries- ED device
Description: The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dornier Aries- ED device
Description: The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
Study: NCT01912625

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Radiation Therapy
Description: Undergo IGRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT03623919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FallSensing multiplayer games
Description: FallSensing multiplayer games is a technological solution based on an interactive (exer)game.~Players will wear a strap on the lower limbs contaning an inertial sensor. This device enables movement identification on the characterization in real time, triggering actions in the game.~The exercise games are based on a validated fall prevention exercise plan - the Otago Exercise Programme. The exercises were designed to promote mobility and improve muscle strength and balance.
Study: NCT01023984

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEM - Transanal Endoscopic Microsurgery
Description: TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESD - Endoscopic Submucosal Dissection
Description: an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
Study: NCT01171651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JX-594 followed by sorafenib
Description: Patients will receive a total dose of 1e9 per treatment starting with one IV dose on Day 1 and injected intratumorally in 1-5 intrahepatic tumors on Day 8 and 22. Starting on Day 25 (3 days after the final JX-594 dose) patients will initiate oral sorafenib therapy twice daily according to standard approved guidelines. An optional maintenance JX-594 dose may be given intratumorally at Week 12 (sorafenib briefly interrupted).
Study: NCT02500693

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isolation of circulating tumor cells (CTC) from veinous blood
Description: Thirty ml of peripheral blood will be collected in buffered EDTA, maintained at 4°C, and processed within 1 hour for filtration. After blood filtration, the membrane will be gently washed with PBS, disassembled from the filtration module, and allowed to air-dry. The determination of CTC number present on filters will be carried out by combining four color immunofluorescent (anti-pancytokeratins/anti-vimentin/DAPI/anti-CD45) staining and cytomorphological examination after Diff-quick and Mayer Hemalun staining in three spots per patient sample. Imaging of immunofluorescent and cytological staining will be performed at x20 magnification using the automated Ariol system. CTCs are identified by relocating images of immunofluorescent and cytological staining.
Study: NCT00495157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom-based adjustment
Description: Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
Study: NCT03613922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physiotherapy
Description: Routine physiotherapy program consisted of range of motion, flexibility and strengthening exercises, and home exercise program was applied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physiotherapy
Description: Routine physiotherapy program consisted of range of motion, flexibility and strengthening exercises, and home exercise program was applied.
Study: NCT02218580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Study: NCT04235881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program
Description: Mindfulness training through an adaptation of the standardized MBSR program. This program was conducted in person and in a group, with a maximum of 25 participants per group and a total duration of 8 weeks. The training was carried out in 8 sessions, one each week, with a duration of 2 h each session.
Study: NCT02319629

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03148691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-101
Description: Topical Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-101
Description: Topical Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A-101
Description: Topical Solution
Study: NCT02674204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance that has no therapeutic effect, and will be used as a control in testing the study agent.
Study: NCT01442844

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Micrografting
Description: Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile dressing that will be placed on the surgical wound.
Study: NCT04244539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-intensity laser Device.
Description: Twenty four treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 8 weeks in succession via HIRO® 3.0 device (ASAlaser, Arcugnano, Vicenza, Italy). The device gives pulsed emission (λ = 1064 nm), maximum power (3000 W), fluency range (360-1780 mJ/cm2), pulse duration (≤ 100 μs), frequency range (10-40 Hz), maximum energy per pulse (350 mJ), mean power (10.5 W), and power cycle of \~0.1%.
Study: NCT03863912

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Disney movie
Description: Disney movie on portable DVD Player.

Intervention type: OTHER
Group type: OTHER
Intervention: EORTC QLQ-C30 and EORTC QLQ-FA12 surveys
Description: EORTC QLQ-C30 and EORTC QLQ-FA12 surveys

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EORTC QLQ-C30 and EORTC QLQ-FA12 surveys
Description: EORTC QLQ-C30 and EORTC QLQ-FA12 surveys
Study: NCT00274833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Erlotinib is available as 25 mg, 100 mg, and 150 mg tablets. It should be administered orally once daily at the prescribed dose specified in the clinical study protocol per dose escalation schema. Preferably, erlotinib should be taken in the morning with up to 200 mL of water at least 1 hour before or 2 hours after a meal.
Study: NCT00495157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biomarker-based adjustment
Description: Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline-based adjustment
Description: Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
Study: NCT00274833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: TMZ is supplied in white opaque, preservative-free, two piece hard gelatin capsules of the following sizes: 100mg capsules, 20mg capsules, and 5mg capsules. TMZ will be a once a day orally administered (75 mg/m2 x BSA x 42 days)set of capsules taken at least two hours after and one hour before a meal.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Concomitant focal RT will be delivered once daily at 2 Gy per fraction, 5 d/wk, for a total of 60 Gy. (6 weeks) as mentioned in therapeutic modalities.
Study: NCT04424563

Intervention type: DEVICE
Intervention: ventilators
Description: all patients in both groups will be ventilated if shocked and no recordable blood pressure

Intervention type: DEVICE
Intervention: ventilators
Description: all patients in both groups will be ventilated if shocked and no recordable blood pressure

Intervention type: DRUG
Intervention: aminocaproic acid
Description: 4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours.

Intervention type: DRUG
Intervention: Novo Seven
Description: 200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (\>10 gm%) another 2 doses of aFVII received
Study: NCT01851538

Intervention type: OTHER
Intervention: Observational study; no intervention.
Study: NCT04434352

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Storz Duolith Low-Intensity Shockwave Therapy
Description: A: Sham - the sham uses an attachment on the hand held probe that mimics the shockwave device, however it does not deliver any shockwaves. Sham will be delivered twice weekly for 3 weeks in the same manner as the LiSWT. The sham treatment will take about 20 minutes to complete.~B: LiSWT delivered twice weekly for 3 weeks, comprising of 3000 shockwaves delivered to the distal penis (1000 shockwaves), base of penis (1000 shockwaves), and corporal bodies on the perineum (500 shockwaves to each crura). LiSWT is delivered into the penile tissue by a small hand held probe that produces low intensity shockwaves. A tranducer head is placed on the left and right sides of the penis. Treatment takes about 20 minutes to complete.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Storz Duolith Low-Intensity Shockwave Therapy
Description: A: Sham - the sham uses an attachment on the hand held probe that mimics the shockwave device, however it does not deliver any shockwaves. Sham will be delivered twice weekly for 3 weeks in the same manner as the LiSWT. The sham treatment will take about 20 minutes to complete.~B: LiSWT delivered twice weekly for 3 weeks, comprising of 3000 shockwaves delivered to the distal penis (1000 shockwaves), base of penis (1000 shockwaves), and corporal bodies on the perineum (500 shockwaves to each crura). LiSWT is delivered into the penile tissue by a small hand held probe that produces low intensity shockwaves. A tranducer head is placed on the left and right sides of the penis. Treatment takes about 20 minutes to complete.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Storz Duolith Low-Intensity Shockwave Therapy
Description: A: Sham - the sham uses an attachment on the hand held probe that mimics the shockwave device, however it does not deliver any shockwaves. Sham will be delivered twice weekly for 3 weeks in the same manner as the LiSWT. The sham treatment will take about 20 minutes to complete.~B: LiSWT delivered twice weekly for 3 weeks, comprising of 3000 shockwaves delivered to the distal penis (1000 shockwaves), base of penis (1000 shockwaves), and corporal bodies on the perineum (500 shockwaves to each crura). LiSWT is delivered into the penile tissue by a small hand held probe that produces low intensity shockwaves. A tranducer head is placed on the left and right sides of the penis. Treatment takes about 20 minutes to complete.
Study: NCT02820467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fluorescence angiography
Description: Injection of indocyanine grey in an antecubital vein at the posology of 0.05 mg/kg
Study: NCT03183544

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit
Description: The patients will receive a single injection of Gallium-68 PSMA-11 to diagnose biochemical relapse of prostate cancer after treatment.
Study: NCT00709956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost (5 µg)
Description: Single dose of iloprost 5 µg using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: iloprost (5 µg)
Description: Single dose of iloprost 5 µg using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose of matching placebo using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single dose of matching placebo using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
Study: NCT01573910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin ophthalmic solution, 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacin ophthalmic solution, 0.3%
Study: NCT03209219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2A
Description: 3×10\^6 IU， subcutaneous or intramuscular injection, qd for × 4 weeks, and qod thereafter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine Pill
Description: 100mg， oral, bid
Study: NCT00643630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetrix
Description: Twice daily topical application

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tetrix
Description: Twice daily topical application
Study: NCT04673097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Icon® resin infiltration
Description: low viscosity resin that can flow through the pores in the enamel surface

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Icon® resin infiltration
Description: low viscosity resin that can flow through the pores in the enamel surface

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MI paste plus
Description: s a superior form of fluoride ions as it also contains CPP-ACP, enhances mineral release without encouraging the formation of calculus.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MI paste plus
Description: s a superior form of fluoride ions as it also contains CPP-ACP, enhances mineral release without encouraging the formation of calculus.
Study: NCT03538769

Intervention type: OTHER
Group type: OTHER
Intervention: electronic alert and clinical decision support system
Description: Providers taking care of patients will receive an electronic alert and will be guided to use a clinical decision support system
Study: NCT02419976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a breath analysis using the Aeonose
Description: using the Aeonose per standard acquisition protocol which spans 15 minutes of which the individuals breaths normally through a sterile disposable mouthpiece with sterile disposable air filters for 10 minutes during signal acquisition while wearing a nose plug. This will be completed in the office setting prior to their endoscopic procedure.~Following their scheduled standard of care endoscopic procedure the patient will be allowed to consume a standardized refreshment (such as juice or soda) prior to discharge from the post procedure area. These refreshments are already provided as standard care. The participant will return to the office setting and repeat the same breath analysis acquisition process that was done prior to the procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aeonose
Study: NCT00854646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Description: The drug is a sterile, concentrated 75mg/mL solution in polyethylene glycol 400, in labeled, sealed glass vials. The Concentrate must be diluted with aqueous infusion solutions (0.9% NaCl, USP and Water for Injection, USP according to instructions) immediately prior to intravenous administration.
Study: NCT01905475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL6326

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05064657

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bubble blowing method
Description: The investigators were used Bubble blowing method and ball squeezing method.~To child were used a ball squeezing method during the blood collection process.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bubble blowing method
Description: The investigators were used Bubble blowing method and ball squeezing method.~To child were used a ball squeezing method during the blood collection process.
Study: NCT01270334

Intervention type: OTHER
Intervention: PH meassurment
Description: meassuring ph USING PROBE

Intervention type: OTHER
Intervention: PH meassurment
Description: meassuring ph USING PROBE
Study: NCT04416802

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: autologous platelet-rich plasma and low-intensity extracorporeal shockwave therapy
Description: The patient who encounters sexual dysfunction and visits our Outpatient Department (OPD) could enter this trial if he meets the inclusion criteria and exclusion criteria.~1. To fill the questionnaires of International index of erectile function (IIEF) and erectile hardness score (EHS) before starting treatment.~2. Li-ESWT treatment weekly for three weeks and PRP injection at the same day after the last Li-ESWT treatment.~3. Coming back at the fourth week and check is there any side effect and fill the questionnaires of IIEF and EHS.~4. Li-ESWT treatment weekly for three weeks starts on fifth week and PRP injection at the same day after the last Li-ESWT treatment.~5. Coming back at the eighth week and check is there any side effect and fill the questionnaires of IIEF and EHS.~6. Coming back at the twelfth week and check is there any side effect and fill the questionnaires of IIEF and EHS.